A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditions

NCT04145570 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Erlotinib HCl 150 mg
DRUG: Tarceva®

Sponsor

Quadras Scientific Solutions